Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARS-CoV-2 Human Challenge Dose Finding Study
NCT04864548Phase 1Unknown
- Sponsor
- University of Oxford
- Start
- May 2021
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of SARS-CoV-2 oral tablet vaccine in coronavirus disease 2019 (COVID-19) (11 arms), sponsored by University of Oxford. Primary endpoints: Occurrence of solicited and unsolicited adverse events at Day 84, Occurrence of adverse events as determined by medical assessment at Day 365 and 1 more. Status: unknown.
02
Drugs
SARS-CoV-2 oral tablet vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04864548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04864548.